Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More good news today and no real movement in pps. Whoever was selling yesterday knew about the news today and went on the offensive with a ton of shorting.
The evidence is mounting that Platinum Montaur is simultaneously shorting NAVB at present AND selling shares they own to control the pps IN AN EFFORT to limit the NAVB market cap for a sale of the company at a pps no higher than 3.50. With the pipeline we have and the revenue potential of Lymphoseek alone WITH THE EXPANDED LABEL IN THE USA AND THE EU, they are STEALING THE COMPANY.
They want to take the company private and ripoff longs. This nonsense has to stop.
My patience is wearing thin with this company. The EU delay is still bleeding the stock.
The company needs an IR firm to increase potential investor awareness of the potential here. Low float - 14 million shares - great products and a Holding Company.
Tick tock.
Some say that 2014 will be the year for Navidea...I'm not sure what they mean as far as pps goes. 4.00 seems impossible given the ongoing dilution concern, real or not.
And as for the salary reductions, considering that over $100 million in market cap was thrown out the window to raise $30 million, I would have thought Pykett should have made no more than $200K, and the tool is still raking in $399,000. RIDICULOUS.
Larson makes $260K this year?!...and owns minimal stock. Management has MUCH to do to restore investor faith in this company.
If they really want to cut costs and boost investor confidence, they should lay off 20-30% of the existing staff...that would be a PR to surge the shareprice, but knowing this management team, another offering is more likely first...say, 50,000,000 shares at 1.75...
I took a starter position of 25,000 shares today. Things seem to be moving...and they damn well better be.
Thanks for reposting this message - flogonuzim is an excellent source of NAVB insight.
I was surprised it held up so well on Friday. I want to see $5 as much as any long, but fully expected to see 1.67 today. Maybe the seller after hours yesterday at 1.85 wasn't so wise afterall - but the buyer of those shares was!
Long and strong.
GLTA.
Don't forget about all the $3 call activity for next month.
Some investors have bet huge that NAVB sees 3.00 within 40 calendar days. All of this talk all of a sudden about a European denial is ridiculous. The company has confidently said, more than once, that they expect EU approval by the end of 2013.
The real surge in pps will be when the FDA approves Lymphoseek for the sNDA terms within 6 months. Profits and revenues could easily be 10X higher than they have been thus far.
Moreover, if European Approval for the expanded label happens, we should see 2.50 because if the EU approves Lymphoseek with the expanded label, it is an excellent bet that the FDA will do the same within 6 months in response to today's sNDA.
The turnaround is real...
GLTA.
The quicker European sales follow approval, the better. Assuming EU Approval by January 1st, 2014, it would be great to see $100,000 in revenue for Q1 2014 from Europe alone (or at least $200,000 for Q2 from Europe alone).
The sNDA could pop us up .40 at once imo.
GLTA.
NAVB short interest down 78,486 shares from 18,675,805 shares to 18,597,319. Less than 1% down (.4%). Are they trying to give us all an early Christmas? Their refusal to cover when the pps was between 1.35 and 1.65 really makes me wonder.
http://online.wsj.com/mdc/public/page/2_3062-shtamex_N-listing.html
CONGRATULATIONS to all longs. The shorts seem to have blown a real chance to do some covering. Let's see after the market closes what the new short interest is. And let's see how high we go today. Those 3.00 January calls might have been a smart bet as well...
Ah, NAVB! Expect the unexpected.
GLTA.
What happens when you give a bum a Mercedes and $50,000 in spending money? He crashes the car and blows the money.
What happens when an incompetent pharmaceuetical company management team tries to bring an excellent product to market? The stock is diluted endless times in a row and shareholders lose hundreds of millions of dollars. Platinu threatens to intervene and potential new investors stay away.
A fair analogy this is...Can a CEO be sued personally for poor performance?
Just asking.
The best news today was that the company addressed market concern over future dilution. The company will partner with other companies to further the existing pipeline, NOT additional dilution. From where I'm sitting, it looks like a slow and steady trend upwards should continue that will be accelerated by the numerous catalysts we are expecting in the next 2 months.
I'm starting to think that we hear today that the sNDA has been submitted. If so, couple that with European Approval later this month and we're off to the races again as 4694 and 5001 gain attention, not to mention RIGS...May the wind be at our backs today.
GLTA.
Anytime.
An sNDA is a supplemental NDA.
When Navidea submits the application in the US to the FDA for Lymphoseek to get an expanded label (more applications of Lymphoseek will equal substantially more revenue.
It seems possible, as tax loss selling into upward momentum is better than having sold into the downward pressure and there may be less tax loss selling of NAVB in December than there was in November.
Many catalysts are expected by EOY. Some say December could see NAVB back at 3.00. I say 2.50 is easily doable with the sNDA alone AND European Approval with the Expanded Label straight away.
GLTA.
PR at 4:00PM? Seems like someone knows something. I like the way the 25,000 shares on the ASK has been chewed down to 10,000 shares now.
Regardless of the reasons why, the main thing that farks me off about HDY is that the concession sat for all of 2013 without a drill in the water. This was precious time.
What a disgusting mess.
I'd like to personally welcome back the buyers!
Maybe we will hear something substantial tomorrow. The smart shorts did some covering between 1.40 and 1.65.
Has anyone else thought that it might have made much more sense for Navidea to do the offering AFTER releasing these two PRs and thus getting a much better price than 2.11 per share? I still maintain that by pricing the company at 2.11, considerable damage was needlessly done to market cap and retail investors. The company should have timed the offering after the RIGS and 5001 news we have just had. Now it seems as if the market could care less.
All I know is that the company damn well better dazzle in everything that they say Thursday. We DO NOT need more of the same old same old rehash of Lymphoseek. We NEED a real update on how well it is selling and why the company thinks the demand is so great that manufacturing is struggling to keep up with demand. LOL.
If Thursday is a flop, then I smell conspiracy. The shorts will have been given another opportunity to pound away at the pps which has become ever so fragile. This conference was first PR'd more than a month ago. THEY DAMN WELL BETTER HAVE MANY GOOD THINGS TO SAY.
If Thursday is a home run then rightly so - the company kicked their shareholders in the face from September 24th through the earnings date. Thursday they have a chance to start cleaning up the mess they have made...
What are folks expecting to be announced at the December 5th SAVE THE DATE Analyst conference in NYC?
More RIGS news? Additional updates on 4694 and 5001?
RIGS news. Outstanding. Now I'm starting to think that the December 5th NYC conference could be a huge catalyst in itself - and rightly so for longs.
Yes we do, but from the action that we saw from November 1st through the 15th, it certainly seemed like minimal covering took place.
Good question. The company only valued itself at 2.11 with the Crede deal and even the Oldtimers don't seem to mind.
We have an sNDA to be submitted by EOY and European approval expected soon. Moreover, the save the date conference in NYC on December 5th could be an opportunity for the company to announce something unexpected (and positive for once).
Many posters seem to think another offering is inevitable within 12-18 months, which happens to be exactly when the company has said that Lymphoseek will be the standard of care. Tick tock. If the company is right, 3.00 should be no problem - but for now, 2.11 may be tough as the company screwed away $100 million in market cap for
$30 million in Crede money and then released very poor sales numbers. The shorts are not covering with a huge treat slammed in their faces! What's next?
We should get the new short interest today. I expect another increase, though how many shares in anyone's guess. The SA article is a nice reminder of many good things, and the author is correct that only the Crede deal was truly news that should have made people sell.
At 1.53, what are the shorts waiting for? I am still asking this question because their choice not to cover at this level seems exceedingly risky, unless of course, the company announces another offering tomorrow for 40,000,000 shares at 1.40. Phase III trials are supposed to be starting and a much anticipated sNDA should be filed soon. These catalysts could easily bring the stock above 2.00 again. If 2014 is really going to be a banner year for Navidea like toonos claims on IV, then the time to cover is now. A buyout in the 3.00-3.50 range would rip the shorts as they would be forced to cover at the buyout price. Why gamble and wait? Unless of course, they know from Pykett, Tulip, and Larson that the next rude surprise for shareholders is coming soon.
Ok. The company couldn't get a break and have the EMA decision prior to December 5th. I imagine that they wanted the decision today so that they could include European plans in their presentations at this NYC conference. Regardless of the EMA decision which will likely be completely favorable, Navidea damn well better present with their best foot forward. As far as I am concerned, they have severely damaged market perception of the company in general and December 5th is their best opportunity to start fixing this disgusting, outrageous, intolerable, deplorable mess that loyal longs find themselves in.
January and February have historically been very good for the stock. Let's see if the company can stop screwing up and do something right.
The shorts that covered between July and September when the pps was 2.80 plus must be the shorts that do no have a direct phone line to Pykett, Tulip, and useless Brent Larson.
Platinum should buy $3,000,000 worth of Lymphoseek and boost sales artificially themselves. Illegal or not, it would help the sales trajectory etc. etc. etc..
Heck, if shorting the stock down and holding it down on all good news is legal, the good guys need to start playing just as dirty - I maintain that unless the shorts are getting direct information from a company insider at Navidea to guide them into making NAVB the most heavily shorted stock on the AMEX then they are reallllllly foolish not to be covering at 1.40. Think about that...and I'm surprised that the Oldtimers are not highlighting the lack of short covering at this time. The pps and volume make it appear as if more shorting is happening, not covering.
Thoughts? I still think 2.40 is more likely than .40. The shorts could cover NOW during tax loss season and take the pps back to 2.00 and they still make millions and millions. The fact that they are waiting to cover is troublesome, though it could also be their swift undoing if the company can surprise us with something great for a change - and they can start by finding a way to undo the damage they did with the Crede deal.
A buyout would be the sweetest victory as it could rip the shorts heads clean off. If we have two Phase III trials that start in 2014 and we get one approval, we should be a 3.00+ valued stock at a minimum with no questions asked. Do the shorts want to risk it?
It's time for Navidea to act responsible financially and cut back their staff by 10 to 20%. The staff that remains can start to really earn their money and work later hours. Other pharmaceutical companies surge in pps when they cut the fat. Navidea should be no different. It's the new American way. As far as I'm concerned, they can start by letting Brent Larson go. He is doing nothing to attract new investors. Also, the insider buys should all be simultaneously doubled on the same day.
And why aren't the shorts covering? It suuuure seems as if they are shorting more at this point. A buyout could destroy them still, but this feels rigged as if they KNOW NOW the company is headed no where within a year.
Can anyone disagree? I'd love to hear if so.
Good post inside. Unfortunately, the company has destroyed investor confidence in management and the stock. The Crede deal was unimaginable pricing the company at 2.11. Couple that with poor sales and shorts not covering at this price. I'm starting to think more bad news is coming (with or without European Approval) and the company (and the shorts) are already well aware of it.
I believe the stock IS significantly undervalued at 1.45. The company is not helping market perception right now, and no one seems to know what will help. You mention several good possible catalysts, but the imminent danger of another financing deal may destroy the company once and for all. It seems to me as if this is the destiny to come.
If European Approval of Lymphioseek is granted and is for the expanded label, THAT in my opinion could really turn things around as the FDA should conceivably follow in granting the extended applications with the anticipated sNDA.
The way the stock is presently trading though, share price and shareholder value seem to be the company's lowest priority by far.
I wonder if European Approval will take NAVB solidly back to 1.75.
It may surge above this pps the day approval is announced, but our shorts have a habit of always finding plenty of shares to short no matter what the occasion. The company may have limited cash, but my optimistic side thinks they are up to something...they damn well better be.
"...by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts."
"SELECTIVE ACQUISITIONS"...that is exactly what the company needs right now. More evidence that they are destined to grow by adding to the pipeline even more.
Announcement of additional European partnerships would help.
Taken from yesterday's PR announcing the arrival of Michael Goldberg to the Navidea Board of Directors:
"Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts."
Clearly, with the NAVB pps at 1.51 the company has much work to do to successfully execute this declared strategy.
Some posters have maintained that all companies that Crede buys stock in do very well in time. In this case, if Crede has not sold (which I find highly unlikely), they are down around $12 million on their shares. Navidea has a relatively new IR firm and Crede wants to make money. Accordingly, they have much work to do as the pps is languishing in the 1.40s. There's no time like the present to turn this ridiculous, disgusting, deliberate mess around.